Majadahonda

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions

• Amyloidosis6 trials
• Metastatic breast cancer4 trials
• Chronic kidney disease3 trials
• Heart failure3 trials
• Chronic lymphocytic leukaemia2 trials
• Lung cancer2 trials
• Dilated cardiomyopathy1 trial
• Liver and biliary tract cancer1 trial
• Mantle cell lymphoma1 trial
• Pancreatic cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 313 trials
• Phase 24 trials
• Phase 11 trial
• Phase 41 trial

Status

• Active, not recruiting10 trials
• Completed6 trials
• Not yet recruiting4 trials
• Recruiting4 trials
• Terminated2 trials
• Withdrawn1 trial

Lead sponsor

• AstraZeneca19 trials
• Alexion Pharmaceuticals, Inc.6 trials
• Acerta Pharma BV1 trial
• MedImmune LLC1 trial

Running trials

• Not yet recruiting

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· Phase 3· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc., Sponsor

• Recruiting

  Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations

  NCT07654855· AstraZeneca· Source

• Recruiting

  A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

  NCT07624305· Phase 3· AstraZeneca· Source

  Contact: AstraZeneca Clinical AstraZeneca Clinical

• Recruiting

  A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

  NCT07647328· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· Phase 2· AstraZeneca· Source

• Recruiting

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· Phase 3· AstraZeneca· Source

• Recruiting

  Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

  NCT06465810· AstraZeneca· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· AstraZeneca· Source

• Active, not recruiting

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Recruiting

  Observational Study Protocol: LIVER-R

  NCT06252753· AstraZeneca· Source

• Recruiting

  PICAROS - Acalabrutinib RWE on 1L CLL in Spain

  NCT05999877· AstraZeneca· Source

• Active, not recruiting

  A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

  NCT05389449· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)

  NCT05981092· Alexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

  NCT04999969· Phase 2· AstraZeneca· Source

• Active, not recruiting

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

  NCT03530397· Phase 1· MedImmune LLC· Source

• Active, not recruiting

  A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

  NCT02970318· Phase 3· Acerta Pharma BV· Source

• Active, not recruiting

  Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

  NCT02453282· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis3 recruiting
• Chronic kidney disease1 recruiting
• Heart failure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Recruiting

  A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

  NCT07029737· Phase 2· AstraZeneca· Source

• Recruiting

  OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

  NCT06355934· AstraZeneca· Source

• Terminated

  An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

  NCT05592483· AstraZeneca· Source

• Terminated

  ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

  NCT05746559· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Completed

  Tracking Treatment Pathways in Adult Patients With Hyperkalemia.

  NCT05408039· AstraZeneca· Source

• Completed

  Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

  NCT04676646· Phase 4· AstraZeneca· Source

• Completed

  Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

  NCT04469465· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Completed

  Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours

  NCT02094261· Phase 2· AstraZeneca· Source

• Completed

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· Phase 3· AstraZeneca· Source